Pfizer Korea's Benefix (nonacog alfa)', which has been used for the treatment of hemophilia B patients in Korea for 15 years, has taken the lead as a once-a-week prophylaxis.

The strategy for treating hemophilia has now become routine prophylactic therapy. The World Federation of Hemophilia recommended prophylaxis as standard treatment in its guidelines revised last year. In the past, the concept of prophylaxis was also aimed at preventing simple bleeding, but now, the goal is to lead a similar life to the general public and achieve a quality of life.

In February, Benefix added an indication of daily prophylaxis with a weekly dosage. What was previously administered 2-3 times a week can n